Anavex Life Sciences Corp...
10.46
-0.09 (-0.85%)
At close: Jan 14, 2025, 3:59 PM
10.63
1.67%
Pre-market Jan 15, 2025, 07:56 AM EST
undefined%
Bid 10.52
Market Cap 886.75M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -0.52
PE Ratio (ttm) -20.11
Forward PE n/a
Analyst Buy
Ask 10.63
Volume 1,490,003
Avg. Volume (20D) 1,832,455
Open 10.58
Previous Close 10.55
Day's Range 10.19 - 10.89
52-Week Range 3.25 - 14.44
Beta undefined

About AVXL

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinica...

Industry Biotechnology
Sector Healthcare
IPO Date Aug 2, 2006
Employees 40
Stock Exchange NASDAQ
Ticker Symbol AVXL

Analyst Forecast

According to 3 analyst ratings, the average rating for AVXL stock is "Buy." The 12-month stock price forecast is $46, which is an increase of 339.98% from the latest price.

Buy 66.67%
Hold 0.00%
Sell 0.00%
Stock Forecasts
3 weeks ago · Source
+29.55%
Anavex Life Sciences shares are trading higher aft... Unlock content with Pro Subscription
2 months ago · Source
+6.73%
Anavex Life Sciences shares are trading higher. HC Wainwright & Co. reiterated a Buy rating on the stock.